UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of November 2026
001-36203
(Commission File Number)
CAN-FITE BIOPHARMA LTD.
(Exact name of Registrant as specified in its charter)
26 Ben Gurion Street
Ramat Gan 5257346 Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
The first three
paragraphs of the press release attached hereto as Exhibit 99.1 are hereby incorporated by reference into the registrant’s Registration
Statements on Form S-8 (File No. 333-227753,
333-271384
and 333-278525)
and Form F-3 (File Nos. 333-236064,
333-276000,
333-281872,
333-262055,
333-294760,
333-298625 and 333-299160), to be a part thereof from the date on which this report is submitted,
to the extent not superseded by documents or reports subsequently filed or furnished.
On November 18, 2026, Can-Fite BioPharma Ltd.
issued a press release entitled “Can-Fite Pivotal Phase III Psoriasis Study Under an FDA- and EMA-agreed protocol: All Patients
Completed Dosing and Interim Analysis Expected Q1 2027”. A copy of this press release is furnished herewith as Exhibit 99.1.
Exhibit
Index
| Exhibit No. |
|
Description |
| 99.1 |
|
Press Release dated November 18, 2026 |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| Date: November 18, 2026 |
By: |
/s/ Motti Farbstein |
| |
|
Motti Farbstein |
| |
|
Chief Executive Officer and Chief Financial Officer |
Exhibit 99.1
Can-Fite Pivotal Phase III Psoriasis Study Under
an FDA- and EMA-agreed protocol: All Patients Completed Dosing and Interim Analysis Expected Q1 2027
The study evaluates oral Piclidenoson and last
patient in the interim-analysis cohort completes treatment
Ramat Gan, Israel, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Can-Fite
BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small
molecule drugs targeting oncological and inflammatory diseases, today announced completion of treatment of the first 247 patients in its
pivotal Phase III study evaluating Piclidenoson for the treatment of moderate-to-severe plaque psoriasis.
The company announced that the last patient in the interim-analysis
cohort of its pivotal Phase III psoriasis study received the final dose of study treatment. Results of the pre-specified interim analysis
are expected to be read out by the Independent Data Monitoring Committee (IDMC) in Q1 2027.
Completion of dosing marks a key milestone toward the interim analysis,
which will evaluate the efficacy and safety of Piclidenoson in patients with moderate-to-severe plaque psoriasis. The Company previously
announced completion of enrolment of the first 247 patients for this analysis.
Piclidenoson is an investigational, orally administered A3 adenosine
receptor agonist that targets inflammatory pathways implicated in psoriasis. Its clinical development program includes a safety database
involving more than 1,500 subjects. If successfully developed and approved, Piclidenoson could offer a unique oral treatment option for
patients requiring long-term management of their disease, with a favorable safety profile that supports chronically administered.
The randomized, double-blind, placebo-controlled study is being conducted
under a protocol agreed with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Patients receive Piclidenoson
3 mg or placebo orally twice daily. The co-primary efficacy endpoints at Week 16 are the proportion of patients achieving at least a 75%
improvement in the Psoriasis Area and Severity Index (PASI 75) and the proportion achieving a static Physician’s Global Assessment
(sPGA) score of 0 or 1, corresponding to clear or almost clear skin.
“Completion of dosing in the interim-analysis cohort brings us
an important step closer to the anticipated results from our pivotal Phase III psoriasis study,” said Motti Farbstein, Chief Executive
Officer of Can-Fite. “We believe Piclidenoson’s oral administration, selective mechanism of action, and favourable safety
profile observed in clinical studies support its potential as a convenient long-term treatment option for patients with psoriasis. We
look forward to reporting the interim results in Q1 2027.”
About Piclidenoson
Piclidenoson is an orally bioavailable, highly selective A3 adenosine
receptor agonist with anti-inflammatory activity demonstrated in both preclinical and clinical studies. The drug has accumulated an extensive
clinical safety database involving more than 1,500 subjects and is being developed as a potential chronic therapy for psoriasis and other
inflammatory diseases. The drug’s mechanism of action entails inhibition of the inflammatory cytokines interleukin 17 and 23 (IL-17
and IL-23) and the induction of apoptosis of patients’ skin cell keratinocytes involved with the disease pathogenicity.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American: CANF)
(TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion
dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company’s lead drug candidate, Piclidenoson, is
being evaluated in a pivotal Phase III study for the treatment of moderate-to-severe plaque psoriasis, which has completed enrollment
of the first 247 patients for a pre-specified interim analysis, with interim efficacy and safety data expected in the first quarter of
2027. Can-Fite’s liver drug, Namodenoson, is being evaluated in a Phase III trial for hepatocellular carcinoma (HCC), a Phase 2b
trial for the treatment of MASH, and in a Phase 2a study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in
the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson
has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company’s
third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience
in over 1,700 patients in clinical studies to date. For more information please visit: www.canfite.com.
Forward-Looking Statements
This press release may contain forward-looking
statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, the development of Piclidenoson,
the timing and results of the planned interim analysis of the Phase III psoriasis study, the safety, efficacy and therapeutic potential
of Piclidenoson, and the potential for Piclidenoson to receive regulatory approval and be commercialized. All statements in this communication,
other than those relating to historical facts, are “forward looking statements”. Forward-looking statements can be identified
by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,”
“should” or “anticipate” or their negatives or other variations of these words or other comparable words or by
the fact that these statements do not relate strictly to historical or current matters. Forward-looking statements relate to anticipated
or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that
have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause
Can-Fite’s actual results, performance or achievements to be materially different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements
to differ materially from those anticipated in these forward-looking statements include, among other things, our market and other conditions,
history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable
terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results
of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates
into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our
product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance
of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation
of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and
maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the
intellectual property rights of others; competitive companies, technologies and our industry; risks related to not satisfying the continued
listing requirements of NYSE American; and statements as to the impact of the political and security situation in Israel on our business.
More information on these risks, uncertainties and other factors is included from time to time in the “Risk Factors” section
of Can-Fite’s Annual Report on Form 20-F filed with the SEC on March 26, 2026 and other public reports filed with the SEC and in
its periodic filings with the TASE. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. Can-Fite undertakes no obligation to publicly update or review any forward-looking
statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities
laws.
Contact:
Motti Farbstein
info@canfite.com
+972-3-9241114